Regarding human immunodeficiency virus (HIV), a prior study indicated that immunotherapy was safe and feasible among patients with non-small-cell lung cancer (NSCLC) and active HIV infection, and the expression of programmed death-ligand 1 (PD-L1) was much higher in infected individuals than in their counterparts [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.